L’Hopital Alexandra Lepeve
- Address
- lock Available on a paid plan
Digestive System Diseases
At L’Hopital Alexandra Lepeve, investigators are conducting studies aimed at improving outcomes for patients with severe alcohol‑related liver injury. The trials evaluate novel therapeutic regimens that combine antioxidants with standard corticosteroid therapy to increase survival and liver function recovery.
- Alcoholic hepatitis
The department currently runs several trials in this area, contributing to the overall portfolio of 18 studies at the site.
Hemic and Lymphatic Diseases
Research in the hematology department targets a broad spectrum of blood‑borne malignancies, including acute leukemias and aggressive lymphomas. Clinical programs test cutting‑edge immunotherapies, stem‑cell transplantation strategies, and minimal residual disease‑guided approaches to boost long‑term remission rates.
- Acute myeloid leukemia
- Diffuse Large B‑Cell Lymphoma
- Peripheral T‑Cell Lymphoma
- Multiple Myeloma
Seven investigators lead these efforts, reflecting the site’s strong commitment to advancing care for patients with hematologic cancers.
Immune System Diseases
Trials focusing on autoimmune blood disorders evaluate innovative biologic combinations designed to restore normal platelet production. The studies compare a subcutaneous belimumab plus rituximab regimen with standard therapy, seeking faster and more durable responses in chronic immune thrombocytopenia.
- Immune thrombocytopenia (ITP)
This work adds a valuable dimension to the site’s clinical research portfolio, addressing unmet needs in immune‑mediated disease.
Neoplasms
Oncology investigations at the center include advanced solid tumors and large‑cell lymphomas, with a focus on immune checkpoint inhibition and antibody‑drug conjugates. Researchers assess whether adding radiotherapy to PD‑1 blockade or combining novel agents with standard chemotherapy can extend survival in patients with stage III/IV disease.
- Advanced non‑small cell lung cancer
- Large B‑Cell Lymphoma
- Follicular Lymphoma
The site’s multidisciplinary team collaborates with national cancer networks to bring these innovative protocols to the Dunkirk region.
Nervous System Diseases
A placebo‑controlled study evaluates the impact of a 30‑week caffeine regimen on cognitive decline in early‑to‑moderate Alzheimer’s disease. The trial measures changes in memory and executive function to determine whether a simple dietary intervention can slow disease progression.
- Alzheimer’s disease
This investigation highlights the department’s commitment to exploring accessible treatments for neurodegenerative conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 49 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 44 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 9 by active trials.
lock +8 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in L’Hopital Alexandra Lepeve
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Etentamig and Daratumumab Versus Daratumumab and Combination Therapy in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma | AbbVie Deutschland GmbH & Co. KG | Phase IV | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 49 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 7 | Unknown | 2019-10-07 | 2026-06-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.